ArticleAntimicrobial agents and chemotherapy2020
Evidence for Expanding the Role of Streptomycin in the Management of Drug-Resistant Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Key resistance-associated mutations in multidrug-resistant tuberculosis: a genomic study from Shanghai, China, with a focus on aminoglycosides.BMC microbiology · 2025Article
- A General Analytic Approach to Predicting the Best Antibiotic Dosing Regimen.bioRxiv : the preprint server for biology · 2025Article
- Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks.Natural products and bioprospecting · 2025Review
- Unlocking potent anti-tuberculosis natural products through structure-activity relationship analysis.Natural products and bioprospecting · 2025Review
- Genomic characterization of multidrug-resistant tuberculosis in Shanghai, China: antibiotic resistance, virulence and transmission.JAC-antimicrobial resistance · 2025Article
- Bifidobacterium adolescentis is resistant to pyrazinamide, isoniazid, and streptomycin.Scientific reports · 2024Article
- Inactivation of the ribosome assembly factor RimP causes streptomycin resistance and impairs motility inAntimicrobial agents and chemotherapy · 2024Article
- Design and Validation of Primer Sets for the Detection and Quantification of Antibiotic Resistance Genes in Environmental Samples by Quantitative PCR.Microbial ecology · 2024Article
- Deficiency in ribosome biogenesis causes streptomycin resistance and impairs motility inbioRxiv : the preprint server for biology · 2024Article
- The profile of genome-wide DNA methylation, transcriptome, and proteome in streptomycin-resistant Mycobacterium tuberculosis.PloS one · 2024Article
- Lineage classification and antitubercular drug resistance surveillance ofMicrobiology spectrum · 2023Article
- Article
- Article
- Article
- Comparative genomics of drug-resistant strains of Mycobacterium tuberculosis in Ecuador.BMC genomics · 2022Article
- Teaching old drugs new tricks.eLife · 2022Article
- A Neglected Challenge in the Analysis of Active Pharmaceutical Substances with Aldehyde Functional Group in Aqueous Matrices.Iranian journal of pharmaceutical research : IJPR · 2022Article
- Framing access to essential medicines in the context of Universal Health Coverage: a critical analysis of health sector strategic plans from eight countries in the WHO African region.BMC health services research · 2022Article
- Evaluation of Mutations Related to Streptomycin Resistance in Mycobacterium tuberculosis Clinical Isolates.Current microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
Abstract
In 2019, the WHO tuberculosis (TB) treatment guidelines were updated to recommend only limited use of streptomycin, in favor of newer agents or amikacin as the preferred aminoglycoside for drug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.